A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of Veligrotug (VRDN-001), a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHV(s) and Subjects with Thyroid Eye Disease (TED)
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Veligrotug (Primary)
- Indications Graves ophthalmopathy
- Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
- Acronyms THRIVE
- Sponsors Viridian Therapeutics
- 10 Sep 2024 Primary endpoint (Proptosis responder rate) has been met as per results presented in the Viridian Therapeutics Media Release.
- 10 Sep 2024 Results presented in the Viridian Therapeutics Media Release.
- 09 Sep 2024 According to a Viridian Therapeutics media release, will host a conference call and webcast to report topline data for the THRIVE phase 3 clinical trial on Tuesday, September 10, 2024 at 8:00am ET.